RNA Polymerase I Gene Expression Analysis for MS Classification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods cannot accurately predict or differentiate between benign multiple sclerosis (BMS) and typical relapsing-remitting multiple sclerosis (RRMS), leading to inadequate treatment and management strategies, as the molecular events underlying BMS are not well understood and prediction is currently retrospective.
Innovation Solution
A method involving the comparison of gene expression levels in the RNA polymerase I pathway in a subject's cells to reference data from pre-diagnosed BMS and RRMS subjects to classify the subject as more likely to have BMS or RRMS, using specific genes like POLR1D, LRPPRC, and RRN3 to inform diagnosis and treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current retrospective methods are used to define BMS patients, then the definition is based on actual long-term outcomes, but prediction of BMS before disease onset or early diagnosis is impossible
Solution Approach 1:
The patent applies preliminary action by measuring RNA polymerase I pathway gene expression levels (such as POLR1D, LRPPRC, and RRN3) in patients early in the disease course, before long-term outcomes are known. This allows prediction of benign MS course prospectively rather than requiring retrospective evaluation after 10+ years of disease follow-up.
Solution Approach 2:
The patent replaces the mechanical/time-based retrospective evaluation system with a molecular biology-based prediction system. Instead of waiting decades for clinical outcomes to define BMS, the invention uses gene expression analysis to predict benign course early, substituting molecular measurement for long-term clinical observation.
2Reliability
If all MS patients receive aggressive treatment, then typical RRMS patients may benefit, but BMS patients are unnecessarily treated with drugs that have significant side effects
Solution Approach 1:
The patent applies local quality by differentiating treatment approaches based on molecular subtype. BMS patients (identified by specific RNA polymerase I pathway gene expression patterns) receive different management than typical RRMS patients. This allows tailoring treatment to the specific molecular characteristics and prognosis of each patient group, avoiding unnecessary aggressive treatment in BMS while ensuring appropriate treatment for RRMS.
Solution Approach 2:
The patent uses parameter changes in gene expression levels (specifically RNA polymerase I pathway genes) to determine treatment strategy. By measuring expression levels of genes like POLR1D, LRPPRC, and RRN3, the system transitions from uniform treatment based on clinical diagnosis alone to differentiated treatment based on molecular parameters, enabling personalized therapy decisions.
3Ease of manufacture
If uniform treatment protocols are applied to all MS patients, then standardization is achieved, but individualized treatment based on disease course prediction is not possible
Solution Approach 1:
The patent applies segmentation by dividing MS patients into distinct molecular subgroups based on RNA polymerase I pathway gene expression patterns. This segments the homogeneous 'MS patient' category into at least two subgroups: those with benign course (BMS) and those with typical relapsing-remitting course (RRMS). This segmentation enables both standardized protocols for each subgroup and personalized medicine overall.
Solution Approach 2:
The patent introduces dynamics into treatment protocols by making treatment decisions adaptable to individual patient molecular profiles. Rather than static uniform treatment for all MS patients, the system dynamically adjusts treatment intensity and type based on gene expression results, allowing the treatment protocol to flex and adapt to each patient's predicted disease course.
Data Source
AI summary
Provided are methods and kits for classifying a subject as being more likely to have benign multiple sclerosis (BMS) or as being more likely to have typical relapsing remitting multiple sclerosis (RRMS). Classification of multiple sclerosis disease course is performed by comparing a level of expression of at least one gene involved in the RNA polymerase I pathway in a cell of the subject to a reference expression data of said at least one gene obtained from a cell of at least one subject pre-diagnosed as having BMS and/or from a cell of at least one subject pre-diagnosed as having typical RRMS, thereby classifying the subject as being more likely to have BMS or as being more likely to have typical RRMS. Also provided are methods of diagnosing and treating multiple sclerosis and methods of monitoring treatment efficiency.